Broad Institute
@broadinstitute.org
A multidisciplinary community of researchers with the mission to better understand the roots of disease and narrow the gap between new biological insights and impact for patients. Broadinstitute.org
Reposted by Broad Institute
Out today in @cp-cell.bsky.social! We studied how environmental stresses like high-fat diets today can prime tumorigenesis months to years in the future (1/n)
December 22, 2025 at 4:35 PM
Out today in @cp-cell.bsky.social! We studied how environmental stresses like high-fat diets today can prime tumorigenesis months to years in the future (1/n)
Study by @ragoninstitute.bsky.social, @mitkochinstitute.bsky.social, @broadinstitute.org team - including @constantine-sci.bsky.social, @drshay.bsky.social, and @shaleklab.bsky.social - suggests a high-fat diet puts liver cells in a state that makes them more susceptible to cancer-causing mutations
High-fat diets make liver cells more likely to become cancerous
Liver cells exposed to too much fat may revert to an immature state that is more susceptible to cancer-causing mutations.
www.broadinstitute.org
December 22, 2025 at 6:07 PM
Study by @ragoninstitute.bsky.social, @mitkochinstitute.bsky.social, @broadinstitute.org team - including @constantine-sci.bsky.social, @drshay.bsky.social, and @shaleklab.bsky.social - suggests a high-fat diet puts liver cells in a state that makes them more susceptible to cancer-causing mutations
Our immune system declines with age. Now the lab of @zhangf.bsky.social has found a way to overcome this decline by temporarily programming liver cells to improve T cells’ ability to fight infection.
New study suggests a way to rejuvenate the immune system
Stimulating the liver to produce some of the signals of the thymus can reverse age-related declines in T-cell populations and enhance response to vaccination.
broad.io
December 17, 2025 at 5:19 PM
Our immune system declines with age. Now the lab of @zhangf.bsky.social has found a way to overcome this decline by temporarily programming liver cells to improve T cells’ ability to fight infection.
Broad and @mgbresearch.bsky.social scientists discovered a potential new drug target for Friedreich’s ataxia, a rare but devastating genetic disorder.
Findings point to path forward for treatment of rare genetic disease
Researchers from Mass General Brigham and the Broad Institute have discovered a potential drug target for the mitochondrial disorder Friedreich’s ataxia, suggesting a path for the development of new m...
broad.io
December 10, 2025 at 5:48 PM
Broad and @mgbresearch.bsky.social scientists discovered a potential new drug target for Friedreich’s ataxia, a rare but devastating genetic disorder.
Reposted by Broad Institute
Drs. Matthew Meyerson and Heidi Greulich from the @broadinstitute.org sit down and discuss how they and Bayer scientists developed the first FDA-approved #CancerDrug to come from a Broad scientific discovery.
🤝 Learn more about their academic-industry alliance: https://bit.ly/4ruQNRl
🤝 Learn more about their academic-industry alliance: https://bit.ly/4ruQNRl
December 3, 2025 at 10:40 PM
Drs. Matthew Meyerson and Heidi Greulich from the @broadinstitute.org sit down and discuss how they and Bayer scientists developed the first FDA-approved #CancerDrug to come from a Broad scientific discovery.
🤝 Learn more about their academic-industry alliance: https://bit.ly/4ruQNRl
🤝 Learn more about their academic-industry alliance: https://bit.ly/4ruQNRl
Congratulations to the recipients of the 2025 BroadIgnite Awards: Pierre Ankomah, Fabio Cunial, Jordan Doman, Ana Gonzalez Ramos, Sarah Pierce, Avanthi Raghavan, and Jackson Weir! Learn how BroadIgnite helps early-career scientists drive biology forward: broad.io/BI2025.
December 4, 2025 at 7:59 PM
Congratulations to the recipients of the 2025 BroadIgnite Awards: Pierre Ankomah, Fabio Cunial, Jordan Doman, Ana Gonzalez Ramos, Sarah Pierce, Avanthi Raghavan, and Jackson Weir! Learn how BroadIgnite helps early-career scientists drive biology forward: broad.io/BI2025.
LAST CALL! Nominations close Friday, December 5 for the 2026 Merkin Prize in Biomedical Technology 🏆. Nominate: merkinprize.org
The 2025 Merkin Prize was awarded to the pioneering scientists behind CAR T-cell therapy. Learn more: youtube.com/watch?v=YM9R...
Video credit: HPN Health
The 2025 Merkin Prize was awarded to the pioneering scientists behind CAR T-cell therapy. Learn more: youtube.com/watch?v=YM9R...
Video credit: HPN Health
December 3, 2025 at 6:57 PM
LAST CALL! Nominations close Friday, December 5 for the 2026 Merkin Prize in Biomedical Technology 🏆. Nominate: merkinprize.org
The 2025 Merkin Prize was awarded to the pioneering scientists behind CAR T-cell therapy. Learn more: youtube.com/watch?v=YM9R...
Video credit: HPN Health
The 2025 Merkin Prize was awarded to the pioneering scientists behind CAR T-cell therapy. Learn more: youtube.com/watch?v=YM9R...
Video credit: HPN Health
Reposted by Broad Institute
A just-published study by Elinor Karlsson, PhD, and Kathryn Lord, PhD, in @pnas.org found no evidence of behavior-associated genetic variations in dogs: direc.to/oaxf
Genetic tests only revealed strong associations for traits like height & leg length. #dogs @elinork.bsky.social @broadinstitute.org
Genetic tests only revealed strong associations for traits like height & leg length. #dogs @elinork.bsky.social @broadinstitute.org
November 24, 2025 at 9:04 PM
A just-published study by Elinor Karlsson, PhD, and Kathryn Lord, PhD, in @pnas.org found no evidence of behavior-associated genetic variations in dogs: direc.to/oaxf
Genetic tests only revealed strong associations for traits like height & leg length. #dogs @elinork.bsky.social @broadinstitute.org
Genetic tests only revealed strong associations for traits like height & leg length. #dogs @elinork.bsky.social @broadinstitute.org
Nominations are open for the $400,000 Merkin Prize in Biomedical Technology!
Do you know a team or individual whose novel device or method has improved diagnosis, treatment, or prevention of human disease?
Nominate them today. Deadline: Dec. 5, 2025
merkinprize.org
Do you know a team or individual whose novel device or method has improved diagnosis, treatment, or prevention of human disease?
Nominate them today. Deadline: Dec. 5, 2025
merkinprize.org
November 24, 2025 at 3:48 PM
Nominations are open for the $400,000 Merkin Prize in Biomedical Technology!
Do you know a team or individual whose novel device or method has improved diagnosis, treatment, or prevention of human disease?
Nominate them today. Deadline: Dec. 5, 2025
merkinprize.org
Do you know a team or individual whose novel device or method has improved diagnosis, treatment, or prevention of human disease?
Nominate them today. Deadline: Dec. 5, 2025
merkinprize.org
Broad scientists Matthew Meyerson and Heidi Greulich discuss the challenges and lessons learned in developing a new lung cancer medicine from Bayer Healthcare Pharmaceuticals that is based on Broad genetic discoveries. @danafarber.bsky.social
Q&A: How an academic-industry alliance is reshaping the way research can lead to new medicines
Broad researchers Matthew Meyerson and Heidi Greulich describe how they and Bayer scientists developed the first FDA-approved cancer drug to come from a Broad scientific discovery.
www.broadinstitute.org
November 21, 2025 at 4:20 PM
Broad scientists Matthew Meyerson and Heidi Greulich discuss the challenges and lessons learned in developing a new lung cancer medicine from Bayer Healthcare Pharmaceuticals that is based on Broad genetic discoveries. @danafarber.bsky.social
Reposted by Broad Institute
The @fda.gov approved sevabertinib for HER2-mutant non-small-cell lung cancer, supported by a multi-year research collaboration with colleagues at the @broadinstitute.org. Learn more: bit.ly/49Q2vjd
Dana-Farber research supports FDA approval of sevabertinib for HER2-mutant lung cancer | Dana-Farber Cancer Institute
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy. The approval reflects a multi-year collaboration led by Dana-Farber Cancer Institute investigators, working closely with colleagues at the Broad Institute.
www.dana-farber.org
November 21, 2025 at 2:30 PM
The @fda.gov approved sevabertinib for HER2-mutant non-small-cell lung cancer, supported by a multi-year research collaboration with colleagues at the @broadinstitute.org. Learn more: bit.ly/49Q2vjd
The US FDA approved the first cancer drug based on Broad discoveries. Developed by Bayer Healthcare Pharmaceuticals through its research alliance with Broad, this drug is approved for a type of lung cancer that previously had few treatment options. @danafarber.bsky.social
FDA approves first cancer drug based on Broad Institute science
Collaboration between Broad Institute and Bayer leads to new treatment for a hard-to-treat type of lung cancer.
www.broadinstitute.org
November 20, 2025 at 3:24 PM
The US FDA approved the first cancer drug based on Broad discoveries. Developed by Bayer Healthcare Pharmaceuticals through its research alliance with Broad, this drug is approved for a type of lung cancer that previously had few treatment options. @danafarber.bsky.social
A team at the Broad Institute co-led by Sarah Pierce, Steven Erwood, and David Liu has developed a new genome-editing strategy that could potentially lead to a one-time treatment for multiple unrelated genetic diseases.
Single prime editing system could potentially treat multiple genetic diseases
Researchers have developed a genome-editing strategy that targets a common cause of roughly 30 percent of rare diseases and could vastly improve access to gene-editing treatments for patients.
www.broadinstitute.org
November 19, 2025 at 6:40 PM
A team at the Broad Institute co-led by Sarah Pierce, Steven Erwood, and David Liu has developed a new genome-editing strategy that could potentially lead to a one-time treatment for multiple unrelated genetic diseases.
Reposted by Broad Institute
The MacArthur Foundation today announced the winner of this year’s 100&Change award: Sentinel at @broadinstitute.org. Sentinel is an outbreak surveillance framework that prevents pandemics through local community empowerment.
Congrats to the Sentinel team, incl. foundation trustee, Pardis Sabeti!
Congrats to the Sentinel team, incl. foundation trustee, Pardis Sabeti!
MacArthur Foundation
The MacArthur Foundation supports creative people and effective institutions committed to building a more just, verdant, and peaceful world. In addition to selecting the MacArthur Fellows, we work to ...
www.macfound.org
November 19, 2025 at 12:36 AM
The MacArthur Foundation today announced the winner of this year’s 100&Change award: Sentinel at @broadinstitute.org. Sentinel is an outbreak surveillance framework that prevents pandemics through local community empowerment.
Congrats to the Sentinel team, incl. foundation trustee, Pardis Sabeti!
Congrats to the Sentinel team, incl. foundation trustee, Pardis Sabeti!
Reposted by Broad Institute
It is a rare thing to be able to award a $100 million grant but today we do so @macfound.org. I’m thrilled to share the Broad Institute’s Sentinel project is @macfound 100&Change Award Recipient!
www.macfound.org/press/press-...
www.macfound.org/press/press-...
Sentinel Awarded $100 Million to Prevent Pandemics
www.macfound.org
November 18, 2025 at 5:07 PM
It is a rare thing to be able to award a $100 million grant but today we do so @macfound.org. I’m thrilled to share the Broad Institute’s Sentinel project is @macfound 100&Change Award Recipient!
www.macfound.org/press/press-...
www.macfound.org/press/press-...
We're thrilled that Sentinel, a pandemic prevention and response program jointly led by @sabetilab.bsky.social and Christian Happi of the Institute of Genomics and Global Health (IGH), Redeemer’s University in Nigeria, is the Award Recipient for @macfound.org’s #100andChange!
MacArthur Foundation’s 100&Change Awards $100 Million to Sentinel to Prevent Pandemics - Lever for Change
CHICAGO, IL — November 18, 2025 — The John D. and Catherine T. MacArthur Foundation has awarded $100 million to the Broad Institute for the…
leverforchange.org
November 18, 2025 at 5:36 PM
We're thrilled that Sentinel, a pandemic prevention and response program jointly led by @sabetilab.bsky.social and Christian Happi of the Institute of Genomics and Global Health (IGH), Redeemer’s University in Nigeria, is the Award Recipient for @macfound.org’s #100andChange!
Join us in Cambridge, MA (or online) on Wednesday, November 19 at 6PM ET for a Broad Discovery Series talk with Niall Lennon, “Entering the Genomic Medicine era: How technology, data, and biology can improve healthcare throughout our lives.” Register: broadinstitute.swoogo.com/Discovery25
November 13, 2025 at 6:28 PM
Join us in Cambridge, MA (or online) on Wednesday, November 19 at 6PM ET for a Broad Discovery Series talk with Niall Lennon, “Entering the Genomic Medicine era: How technology, data, and biology can improve healthcare throughout our lives.” Register: broadinstitute.swoogo.com/Discovery25
The 2026 Merkin Prize is now accepting nominations!
The Prize is a $400,000 award for transformative technologies and pioneering innovators.
The Merkin Prize recognizes:
🔹 Real-world impact
🔹 Innovation
🔹 Teams and individuals
Nominate by December 5, 2025: merkinprize.org
The Prize is a $400,000 award for transformative technologies and pioneering innovators.
The Merkin Prize recognizes:
🔹 Real-world impact
🔹 Innovation
🔹 Teams and individuals
Nominate by December 5, 2025: merkinprize.org
November 12, 2025 at 4:42 PM
The 2026 Merkin Prize is now accepting nominations!
The Prize is a $400,000 award for transformative technologies and pioneering innovators.
The Merkin Prize recognizes:
🔹 Real-world impact
🔹 Innovation
🔹 Teams and individuals
Nominate by December 5, 2025: merkinprize.org
The Prize is a $400,000 award for transformative technologies and pioneering innovators.
The Merkin Prize recognizes:
🔹 Real-world impact
🔹 Innovation
🔹 Teams and individuals
Nominate by December 5, 2025: merkinprize.org
On Wednesday, November 19 at 6PM ET, join us in Cambridge, MA (or online) for a Broad Discovery Series talk with Niall Lennon, “Entering the Genomic Medicine era: How technology, data, and biology can improve healthcare throughout our lives.” Register: broadinstitute.swoogo.com/Discovery25
November 7, 2025 at 7:03 PM
On Wednesday, November 19 at 6PM ET, join us in Cambridge, MA (or online) for a Broad Discovery Series talk with Niall Lennon, “Entering the Genomic Medicine era: How technology, data, and biology can improve healthcare throughout our lives.” Register: broadinstitute.swoogo.com/Discovery25
Reposted by Broad Institute
Announcing our new preprint! We built SPICE, a framework that combines large-scale experiments and generative AI to design RNA sequences that control cell type-specific gene expression using alternative splicing – a powerful, underexplored modality.
Preprint: www.biorxiv.org/content/10.1...
(1/10)
Preprint: www.biorxiv.org/content/10.1...
(1/10)
Generative Design of Cell Type-Specific RNA Splicing Elements for Programmable Gene Regulation
Programmable control of gene expression in specific cell types is essential for both basic discovery and therapeutic intervention, yet current strategies lack scalability across diverse cellular conte...
www.biorxiv.org
November 6, 2025 at 6:59 PM
Announcing our new preprint! We built SPICE, a framework that combines large-scale experiments and generative AI to design RNA sequences that control cell type-specific gene expression using alternative splicing – a powerful, underexplored modality.
Preprint: www.biorxiv.org/content/10.1...
(1/10)
Preprint: www.biorxiv.org/content/10.1...
(1/10)
Reposted by Broad Institute
New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org
Read more at bit.ly/4onnFJO
Read more at bit.ly/4onnFJO
November 6, 2025 at 7:30 PM
New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org
Read more at bit.ly/4onnFJO
Read more at bit.ly/4onnFJO
Reposted by Broad Institute
We’re proud to be part of this new @broadinstitute.org effort! In this Q&A Picower researchers Sara Prescott and Ravi Raju describe the project, how they’re involved, and the research they’re doing: picower.mit.edu/news/qa-pico...
November 4, 2025 at 4:29 PM
We’re proud to be part of this new @broadinstitute.org effort! In this Q&A Picower researchers Sara Prescott and Ravi Raju describe the project, how they’re involved, and the research they’re doing: picower.mit.edu/news/qa-pico...
Broad has launched the Biology of Adversity Project, led by
@jbuenrostro.bsky.social a 2023 @macfound.org fellow, to uncover how adverse life experiences can inflict molecular “scars” in the genome and body and increase risk of heart disease and other disorders. Learn more: broad.io/BAP
@jbuenrostro.bsky.social a 2023 @macfound.org fellow, to uncover how adverse life experiences can inflict molecular “scars” in the genome and body and increase risk of heart disease and other disorders. Learn more: broad.io/BAP
November 4, 2025 at 4:26 PM
Broad has launched the Biology of Adversity Project, led by
@jbuenrostro.bsky.social a 2023 @macfound.org fellow, to uncover how adverse life experiences can inflict molecular “scars” in the genome and body and increase risk of heart disease and other disorders. Learn more: broad.io/BAP
@jbuenrostro.bsky.social a 2023 @macfound.org fellow, to uncover how adverse life experiences can inflict molecular “scars” in the genome and body and increase risk of heart disease and other disorders. Learn more: broad.io/BAP
Reposted by Broad Institute
Congrats to Jinjin Xu & co-authors – an image from their recent @jem.org article that describes Ankrd55 as a modulator of T cell metabolism impacting Th17 responses was selected for the cover!
Read the study here: rupress.org/jem/article-...
@broadinstitute.org @mgbresearch.bsky.social
Read the study here: rupress.org/jem/article-...
@broadinstitute.org @mgbresearch.bsky.social
November 4, 2025 at 2:47 PM
Congrats to Jinjin Xu & co-authors – an image from their recent @jem.org article that describes Ankrd55 as a modulator of T cell metabolism impacting Th17 responses was selected for the cover!
Read the study here: rupress.org/jem/article-...
@broadinstitute.org @mgbresearch.bsky.social
Read the study here: rupress.org/jem/article-...
@broadinstitute.org @mgbresearch.bsky.social
A new @natgenet.nature.com study by Broad, @mgbresearch.bsky.social, and VA Boston collaborators reveals a genetic variant that helps explain the high dilated cardiomyopathy risk in people of African ancestry.
Genetic variant increases risk of heart muscle disease common in individuals of African ancestry
A single mutation in the CD36 gene, present in 17 percent of people with African ancestry, increases a person's dilated cardiomyopathy risk by 33 percent.
broad.io
October 31, 2025 at 3:28 PM
A new @natgenet.nature.com study by Broad, @mgbresearch.bsky.social, and VA Boston collaborators reveals a genetic variant that helps explain the high dilated cardiomyopathy risk in people of African ancestry.